Overview of the Applied Therapeutics Class Action
A recent class-action lawsuit has emerged against Applied Therapeutics, Inc. (NASDAQ: APLT), a clinical-stage biopharmaceutical company. This legal action has been initiated by investors who feel they were misled regarding the company's drug candidate and its approval process. If you invested in Applied Therapeutics, this may directly impact your rights as a shareholder.
Understanding the Lawsuit
The law firm Bleichmar Fonti & Auld LLP has filed a suit on behalf of investors. The case alleges that the company and certain executives possibly violated securities laws. These claims have heightened the scrutiny on the company's operations and its communication to shareholders.
What Are the Allegations?
The allegations center around statements made by Applied Therapeutics regarding its lead drug candidate, govorestat. The company had previously claimed that its New Drug Applications were robust, backed by data indicating significant clinical benefits and safety for patients, particularly regarding rare diseases. Investors believed these claims to be truthful, which has now been called into question.
Impact of the FDA's Response
On November 27, 2024, Applied Therapeutics faced a critical blow when it announced that the FDA had issued a Complete Response Letter for its NDA for govorestat. The letter indicated that the FDA could not approve the application due to identified deficiencies, leading to a severe drop in the stock price.
Stock Price Decline
The fallout from this FDA letter was significant, with the stock losing over 80% of its value in just a few days, plummeting from $10.21 to $1.75 per share. Subsequently, on December 2, additional news emerged regarding a warning letter from the FDA, further exacerbating the situation and triggering another decline to $1.29 per share.
What Should Investors Do?
Investors who suffered losses due to these events are encouraged to take action. The lawsuit provides an opportunity for affected shareholders to seek compensation. Those interested in participating in the case have until February 18, 2025, to make their intentions known.
Legal Representation and Fees
Bleichmar Fonti & Auld LLP operates on a contingency fee basis, meaning there are no upfront costs for shareholders to join the lawsuit. If successful, any fees and expenses would be subject to court approval, ensuring transparency in the process.
Why Choose Bleichmar Fonti & Auld LLP?
The firm has garnered a reputation as a leading entity in securities class actions, having achieved significant recoveries in previous cases. Their expertise provides shareholders with a reliable choice when navigating complex legal matters.
Contacting the Firm
Investors seeking more information or wishing to submit their details for potential involvement can visit the firm's website. They can also contact attorney Ross Shikowitz directly at 212-789-3619 or via email.
Frequently Asked Questions
What is the deadline for joining the lawsuit?
The deadline for investors to join the lawsuit is February 18, 2025.
Who is representing the investors?
Bleichmar Fonti & Auld LLP is representing the investors in this class action lawsuit.
What caused the steep decline in stock prices?
The stock prices fell due to the FDA's Complete Response Letter citing deficiencies in the NDA for govorestat and subsequent warnings regarding data issues.
Are there any costs associated with joining the lawsuit?
No, representation is on a contingency fee basis, meaning no costs are incurred until a recovery is achieved.
How can investors get more information?
Investors can visit the Bleichmar Fonti & Auld LLP website or contact the firm directly for more information and guidance.
